Pharmaceuticals

Recent progress towards Unitary Patent and Unified Patent Court Europe’s long-awaited Unified Patent Court and the European Union’s Unitary Patent could (and even should) both be available before the end of 2022. Even if there is a short delay, the UPC is almost certain to be open for business in late 2022 or early 2023…. Read more »

Pharmaceutical team member Suzanne Power provides a round-up of UK Trade Mark case law in pharma goods and medical devices This article was published in the December issue of PTMG’s Law, Lore & Practice With the UK IPO having seen record numbers of trade mark applications over the past year, a steady stream of objections,… Read more »

Exhausted? You’re not alone…! What next for parallel imports after Brexit? This article was first written by our experts Ian Gill and Suzanne Power for PTMG’s Law Lore & Practice Newsletter   Background 1 January 2021 marked the start of a new era for the United Kingdom and European Union. On that date, some four… Read more »

The Nagoya Protocol and the UK – are you compliant? The Nagoya Protocol has been in force in the UK since October 2015 and obliges users of genetic resources and traditional knowledge associated with genetic resources to comply with due diligence requirements before its ‘utilisation’. There is also an obligation to make a due diligence… Read more »

Deadline approaching for the Government R&D Tax Credits Consultation – your input needed for potential changes to RDEC and SME R&D Relief Government R&D Tax Credits Consultation: The UK government intends to raise investment in research and development to 2.4% of UK GDP by 2027 and wants to ensure that one of the key incentives for… Read more »

Trade marks in AI 2021 – Sarah Neil shares an update on the progress in the UK’s review of artificial intelligence and intellectual property   As we have mentioned in previous articles trade marks in AI are an important part of a strong portfolio in the protection of your AI business. The ever accelerating landscape… Read more »

AA Thornton’s Pharma & Biotech experts contribute to the European Patent Office’s peer consultation on the EPOs Guidelines for Examination; Part G chapter II,  section 5.6 concerning Antibodies. On 1st March 2021 the EPO published new guidelines for the examination of claims to antibodies which has raised some some specific concerns regarding the proposed wording… Read more »

Amgen v Sanofi and Regeneron: Broad antibody patents held invalid for lack of enablement in US Lack of enablement: A conclusion of lack of enablement means that the disclosure provided in the patent specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full… Read more »

Partner Dr. Lawrence King reflects on Patenting in the Pandemic and the importance of locking down innovation in troubled times in this article, first published in The Chemical Engineer. The importance of locking down innovation in troubled times TO MOST, A Poor Man’s Tale of a Patent, published in October 1850, remains one of Charles Dickens’ lesser-known… Read more »

Partners Mike Jennings and Alex Bone explore the UKIPO “Green Channel” At AA Thornton, our patent attorneys have a long history of assisting innovators seeking protection for a variety of green technology including solar technology, waste processing and wind turbines.  Some of our clients were kind enough to share their stories with us, and you… Read more »